Dr. Nancy L. Bartlett, MD
Medical Oncology (Medical Oncology Physician)
4921 Parkview Pl, Div Im Medical Oncology, Ste 7a, 7b, 7c
Saint Louis, MO 63110
- Medicare participating
At a glance
- Medical school
- Washington University School of Medicine (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 698
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: Washington University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MO license 104872
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
- Missouri Baptist Medical Center Saint Louis, MO
- Barnes-Jewish West County Hospital Creve Coeur, MO
- Memorial Hospital Belleville, IL
- Barnes-Jewish St Peters Hospital Saint Peters, MO
Medical groups
- Washington University (3,029 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 698
- Services billed
- 34,167
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, fosaprepitant, 1 mg | 5,850 | 21 |
| Injection, pembrolizumab, 1 mg | 5,200 | 11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,700 | 87 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,550 | 17 |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 1,230 | 18 |
| Injection, palonosetron hcl, 25 mcg | 1,030 | 64 |
| Insertion of needle into vein for collection of blood sample | 809 | 371 |
| Established patient office or other outpatient visit, 30-39 minutes | 766 | 393 |
| Injection, leucovorin calcium, per 50 mg | 613 | 15 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 420 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Saint Louis, MO | 464 |
| Brukinsa (zanubrutinib) | 164 |
| Prednisone Other prescribers in Saint Louis, MO | 133 |
| Calquence (acalabrutinib maleate) | 131 |
| Prochlorperazine Maleate Other prescribers in Saint Louis, MO | 81 |
| Gabapentin Other prescribers in Saint Louis, MO | 71 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Saint Louis, MO | 71 |
| Omeprazole Other prescribers in Saint Louis, MO | 67 |
| Levothyroxine Sodium Other prescribers in Saint Louis, MO | 64 |
| Ondansetron Hcl Other prescribers in Saint Louis, MO | 61 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 6 payments worth $559 in total to this clinician.
| Taiho Oncology, Inc. | $422 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $107 |
| Abbott Laboratories | $29.93 |
| Speaking at a medical education program | $272 |
|---|---|
| Travel and Lodging | $258 |
| Food and Beverage | $29.93 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Taiho Oncology, Inc. Oct 31, 2025 | Speaking at a medical education program | $272 |
| AstraZeneca Pharmaceuticals LP Aug 23, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $107 |
| Taiho Oncology, Inc. Nov 15, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $72.88 |
| Taiho Oncology, Inc. Aug 23, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $63.65 |
| Taiho Oncology, Inc. Oct 31, 2025 | Travel and Lodging travel to San Diego, CA | $14.14 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 6 companies. The companies reported $1,425,339 in research payments for these studies, mostly to the institutions running them.
- Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma
Genentech, Inc. - M pola in 1L FL
Genentech, Inc. - Phase 1 EIH CD19 4 1BBL
Genentech, Inc. - A randomized doubleblind placebocontrolled activecomparator multicenter phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse la…
Pfizer Inc. - A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma
E.r. Squibb & Sons, L.l.c. · Completed · NCT01650701 - Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL
Genentech, Inc. - A Phase 1/2a, Open-Label, Dose Escalation Trial of GEN3017 With Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma
Genmab A/s - M DHAX ICE in R R B NHL
Genentech, Inc. - An open-label, multicenter, phase i/ii trial evaluating the safety, efficacy, and pharmacokinetics of escalating doses of mosunetuzumab (BTCT4465A) as a single agent and combined with atezolizumab in patients with rel…
Genentech, Inc. - Glofitamab ctDNA study
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.